vs
Side-by-side financial comparison of BridgeBio Pharma, Inc. (BBIO) and LiveRamp Holdings, Inc. (RAMP). Click either name above to swap in a different company.
LiveRamp Holdings, Inc. is the larger business by last-quarter revenue ($212.2M vs $154.2M, roughly 1.4× BridgeBio Pharma, Inc.). LiveRamp Holdings, Inc. runs the higher net margin — 18.8% vs -126.2%, a 145.0% gap on every dollar of revenue. On growth, BridgeBio Pharma, Inc. posted the faster year-over-year revenue change (2521.2% vs 8.6%).
Brent Saunders is an American biopharma executive and entrepreneur who is the chairman and CEO of the health company Bausch & Lomb. He helped lead various mergers and acquisitions, including the mergers between Merck and Schering-Plough, the acquisition of Bausch + Lomb by Valeant Pharmaceuticals, and the $63 billion acquisition of Allergan by Abbvie. He founded the special-purpose acquisition company (SPAC) Vesper Healthcare Acquisition. Saunders is also executive chairman of medical aesthet...
LiveRamp Holdings, Inc., is an American SaaS company that offers a data connectivity platform whose services include data onboarding, the transfer of offline data online for marketing purposes.
BBIO vs RAMP — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2026
| Metric | | |
|---|---|---|
| Revenue | $154.2M | $212.2M |
| Net Profit | $-194.6M | $39.9M |
| Gross Margin | 94.7% | 71.9% |
| Operating Margin | -90.5% | 18.6% |
| Net Margin | -126.2% | 18.8% |
| Revenue YoY | 2521.2% | 8.6% |
| Net Profit YoY | 27.2% | 255.7% |
| EPS (diluted) | $-1.00 | $0.62 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $154.2M | $212.2M | ||
| Q3 25 | $120.7M | $199.8M | ||
| Q2 25 | $110.6M | $194.8M | ||
| Q1 25 | $116.6M | $188.7M | ||
| Q4 24 | — | $195.4M | ||
| Q3 24 | — | $185.5M | ||
| Q2 24 | — | $176.0M | ||
| Q1 24 | $211.1M | $171.9M |
| Q4 25 | $-194.6M | $39.9M | ||
| Q3 25 | $-184.9M | $27.4M | ||
| Q2 25 | $-183.8M | $7.7M | ||
| Q1 25 | $-169.6M | $-6.3M | ||
| Q4 24 | — | $11.2M | ||
| Q3 24 | — | $1.7M | ||
| Q2 24 | — | $-7.5M | ||
| Q1 24 | $-36.2M | $-5.4M |
| Q4 25 | 94.7% | 71.9% | ||
| Q3 25 | 94.6% | 70.2% | ||
| Q2 25 | 96.7% | 70.1% | ||
| Q1 25 | 97.7% | 69.3% | ||
| Q4 24 | — | 71.9% | ||
| Q3 24 | — | 72.4% | ||
| Q2 24 | — | 70.6% | ||
| Q1 24 | 99.7% | 72.2% |
| Q4 25 | -90.5% | 18.6% | ||
| Q3 25 | -120.3% | 10.7% | ||
| Q2 25 | -121.4% | 3.7% | ||
| Q1 25 | -89.5% | -6.1% | ||
| Q4 24 | — | 7.5% | ||
| Q3 24 | — | 4.0% | ||
| Q2 24 | — | -3.0% | ||
| Q1 24 | 0.2% | -8.3% |
| Q4 25 | -126.2% | 18.8% | ||
| Q3 25 | -153.2% | 13.7% | ||
| Q2 25 | -166.2% | 4.0% | ||
| Q1 25 | -145.4% | -3.3% | ||
| Q4 24 | — | 5.7% | ||
| Q3 24 | — | 0.9% | ||
| Q2 24 | — | -4.3% | ||
| Q1 24 | -17.1% | -3.1% |
| Q4 25 | $-1.00 | $0.62 | ||
| Q3 25 | $-0.95 | $0.42 | ||
| Q2 25 | $-0.95 | $0.12 | ||
| Q1 25 | $-0.88 | $-0.10 | ||
| Q4 24 | — | $0.17 | ||
| Q3 24 | — | $0.03 | ||
| Q2 24 | — | $-0.11 | ||
| Q1 24 | $-0.20 | $-0.09 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $570.1M | $403.4M |
| Total DebtLower is stronger | $2.0B | — |
| Stockholders' EquityBook value | $-2.1B | $962.3M |
| Total Assets | $936.0M | $1.3B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $570.1M | $403.4M | ||
| Q3 25 | $643.0M | $376.9M | ||
| Q2 25 | $756.9M | $371.1M | ||
| Q1 25 | $540.6M | $420.8M | ||
| Q4 24 | — | $384.3M | ||
| Q3 24 | — | $348.4M | ||
| Q2 24 | — | $342.7M | ||
| Q1 24 | $519.7M | $368.9M |
| Q4 25 | $2.0B | — | ||
| Q3 25 | $2.0B | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $-2.1B | $962.3M | ||
| Q3 25 | $-1.9B | $943.8M | ||
| Q2 25 | $-1.8B | $947.8M | ||
| Q1 25 | $-1.6B | $948.9M | ||
| Q4 24 | — | $957.7M | ||
| Q3 24 | — | $932.1M | ||
| Q2 24 | — | $951.9M | ||
| Q1 24 | $-1.0B | $949.1M |
| Q4 25 | $936.0M | $1.3B | ||
| Q3 25 | $998.3M | $1.2B | ||
| Q2 25 | $1.1B | $1.2B | ||
| Q1 25 | $881.6M | $1.3B | ||
| Q4 24 | — | $1.3B | ||
| Q3 24 | — | $1.2B | ||
| Q2 24 | — | $1.2B | ||
| Q1 24 | $849.3M | $1.2B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-56.4M | — |
| Free Cash FlowOCF − Capex | $-56.5M | — |
| FCF MarginFCF / Revenue | -36.6% | — |
| Capex IntensityCapex / Revenue | 0.0% | 0.1% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-56.4M | — | ||
| Q3 25 | $-109.6M | $57.4M | ||
| Q2 25 | $-80.7M | $-15.8M | ||
| Q1 25 | $-199.2M | — | ||
| Q4 24 | — | $45.1M | ||
| Q3 24 | — | $55.6M | ||
| Q2 24 | — | $-9.3M | ||
| Q1 24 | $-219.5M | — |
| Q4 25 | $-56.5M | — | ||
| Q3 25 | $-110.0M | $56.8M | ||
| Q2 25 | $-81.3M | $-16.2M | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $44.8M | ||
| Q3 24 | — | $55.4M | ||
| Q2 24 | — | $-9.6M | ||
| Q1 24 | $-220.2M | — |
| Q4 25 | -36.6% | — | ||
| Q3 25 | -91.2% | 28.4% | ||
| Q2 25 | -73.5% | -8.3% | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 22.9% | ||
| Q3 24 | — | 29.8% | ||
| Q2 24 | — | -5.4% | ||
| Q1 24 | -104.3% | — |
| Q4 25 | 0.0% | 0.1% | ||
| Q3 25 | 0.4% | 0.3% | ||
| Q2 25 | 0.5% | 0.2% | ||
| Q1 25 | 0.0% | 0.2% | ||
| Q4 24 | — | 0.1% | ||
| Q3 24 | — | 0.1% | ||
| Q2 24 | — | 0.1% | ||
| Q1 24 | 0.3% | 1.0% |
| Q4 25 | — | — | ||
| Q3 25 | — | 2.09× | ||
| Q2 25 | — | -2.04× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 4.02× | ||
| Q3 24 | — | 32.10× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
